GlobeNewswire Inc | Jul 9, 2021 08:36AM EDT

July 09, 2021

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

Panel Details:Title: Next Generation Small Molecules in OncologyPanel date and time: Thursday, July 15, 9:00 a.m. ET

A live webcast of the panel can be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com.

About Foghorn Therapeutics

Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavali, Foghorn Therapeutics fcavalie@foghorntx.com

Gregory Kelley, Ogilvy gregory.kelley@ogilvy.com

Investor Relations Contact:

Allan Reine, Foghorn Therapeutics areine@foghorntx.com

Hans Vitzthun, LifeSci Advisors617-430-7578hans@lifesciadvisors.com